Innovation Showcase: Menten AI, Inc. Menten AI's CEO, Hans Melo, and VP of Business Development, Andrea McNeal, attended and presented at BioEurope 2025 this November 3–5. The event brings together global leaders in biotechnology and pharma to explore collaborations and innovation in drug discovery. We look forward to sharing Menten AI’s latest advances in AI-driven protein design and connecting with partners shaping the future of biotech.

Read more

We’re thrilled to welcome Andrea McNeal as our new Vice President of Business Development! Andrea will lead our efforts to expand strategic collaborations and help scale our AI-driven peptide design platform.

Read more

Menten AI was invited by the Swiss Chemical Society to present at the 2025 Peptide Therapeutics Forum, where CEO Hans Melo highlighted the recent advancements of our platform.

Read more

Menten AI showcased peptide drug innovations at NextGen Biomed and BIO-Europe Spring, strengthening industry connections and advancing the future of peptide-based drugs.

Read more

Menten AI's CEO, Dr. Hans Melo, will be sharing the latest developments at Menten AI in Stockholm on adding drug-like properties including plasma stability and membrane-permeability.

Read more

Menten AI's CEO, Dr. Hans Melo, will be sharing the latest developments at Menten AI in Boulder on adding drug-like properties including plasma stability and membrane-permeability.

Read more

Menten AI and Google Collaborate to Accelerate Innovation in Drug Discovery.

Read more

Menten AI and co-founder Vikram Mulligan featured in C&EN's cover on the potential of peptide macrocycles as drugs.

Read more

A collaboration with BMS leverages Menten AI’s generative AI platform to accelerate the design and optimization of peptide macrocycles.

Read more

Quantum computing has the potential to bust through some of today’s toughest challenges, advancing everything from drug discovery to weather forecasting. In short, quantum computing will play a huge role in HPC’s future.

Read more

Registration is free for this online quantum computing conference featuring innovation-centered talks by the chief executives shaping the future of quantum computing and world-leading business experts

Read more

Menten AI selects Xanadu's open-source library PennyLane to leverage quantum simulation and quantum machine learning capabilities to develop novel protein-based drugs.

Read more

Dr. Melo, CEO of Menten AI, emphasized at the Spring BioEurope conference the substantial decrease in design timelines enabled by our platform, and reiterated the company's dedication to aiding partners in their drug discovery initiatives.

Read more

Dr. Finneran's recent appearance on Software Engineering Daily highlights Menten AI's significant commitment to computational drug discovery, as he discussed the intersection of our platform with software engineering and AI.

Read more

Dr. Patrick Finneran represented Menten AI at Winter RosettaCon 2024 and discussed how Menten AI uses physics based generative AI to design cyclic peptides with drug-like properties.

Read more

Menten AI joins Ginkgo Technology Network to enhance R&D with advanced AI for cyclic peptide design, helping partners achieve optimal outcomes.

Read more

Menten AI co-authors chapter on quantum computing in Wiley’s new book "Computational Drug Discovery: Methods and Applications" where quantum computing is discussed in the context of computational drug design.

Read more

Dr. Stephan Kudlacek represented Menten AI at APS 2023 this year and discussed how Menten AI developed the world’s most advanced generative AI platform for the design and optimization of macrocyclic peptide therapeutics.

Read more

Menten AI releases Menten GCN: a python library to create GCN tensors from protein models for machine learning.

Read more

We’re excited to release XENet a new graph convolution that allows larger protein design problems to fit onto near-term quantum computers.

Read more

Fresh off the press! New Nature review of tools for macromolecular design developed in the last 5 years by the Rosetta community. Including Menten AI's team members Jack Maguire and Vikram K. Mulligan.

Read more

We're super excited to announce that Menten AI is now funded by Y Combinator! We're extremely grateful to everyone at Y Combinator for their guidance, especially in these unprecedented times.❤️🙏

Read more

Our approach, Qpacker, demonstrates that quantum-annealer-based design can be applied to complex real-world design tasks, producing designed molecules comparable to those produced by widely adopted classical design approaches.

Read more

Allosteric regulation of protein function is widespread in biology, but is challenging for de novo protein design as it requires the explicit design of multiple states with comparable free energies.

Read more

Menten AI created the world’s first protein designed on a quantum computer.

Read more

Quantum computing promises plenty, such as how it can massively accelerate some bioinformatics calculations.

Read more

D-Wave Systems, the company that was the first to sell a commercial quantum computer, has unveiled its newest and most powerful model to date.

Read more

CEO of PCIS. Entrepreneur with a deep focus on technology. Helping companies strategize, innovate and grow.

Read more

The startup, backed by Y Combinator among others, aims to develop biologics, or drugs made from organic rather than synthetic material

Read more

Menten AI has an impressive founding team and a pitch that combines some of the hottest trends in tech to pursue one of the biggest problems in healthcare — new drug discovery.

Read more

Government backs joint project to avoid future pandemics with better forecasting and pre-design of effective vaccines, antibodies and tests

Read more